Clinically available pharmacogenomics tests
- PMID: 19369936
- PMCID: PMC2730436
- DOI: 10.1038/clpt.2009.39
Clinically available pharmacogenomics tests
Abstract
The development of robust and clinically valuable pharmacogenomic tests has been anticipated to be one of the first tangible results of the Human Genome Project. Despite both obvious and unanticipated obstacles, a number of tests have now become available in various practice settings. Lessons can be learned from examination of these tests, the evidence that has catalyzed their use, their value to prescribers, and their merit as tools for personalizing therapeutics.
References
-
- Ng PC, Zhao Q, Levy S, Strausberg RL, Venter JC. Individual genomes instead of race for personalized medicine. Clin. Pharmacol. Ther. 2008;84:306–309. - PubMed
-
- Feero WG, Guttmacher AE, Collins FS. The genome gets personal—almost. JAMA. 2008;299:1351. - PubMed
-
- Epstein RS, et al. Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics. 2009;10:149. - PubMed
-
- Obama B. The Genomics and Personalized Medicine Act of 2006. Clin. Adv. Hematol. Oncol. 2007;5:39–40. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
